Harvard Bioscience, Inc. (HBIO)
NASDAQ: HBIO · Real-Time Price · USD
9.00
-0.08 (-0.88%)
Nov 18, 2026, 4:00 PM EST - Market closed
Harvard Bioscience Revenue
Harvard Bioscience had revenue of $22.20M in the quarter ending September 30, 2026, with 7.79% growth. This brings the company's total for the last twelve months to $89.41M, up 2.34% year-over-year. In the year 2025, Harvard Bioscience had annual revenue of $86.55M, down -8.06%. That makes Harvard Bioscience the 23,580th largest company in the world by revenue and 3,369th in the United States.
Revenue (ttm)
$89.41M
Revenue Growth
+2.34%
P/S Ratio
0.46
Revenue / Employee
$263,755
Employees
339
Market Cap
41.16M
Revenue by Geography
- United States 38.97M 45.0%
- Europe, Middle East and Africa 26.71M 30.9%
- China 10.97M 12.7%
- Asia - Other 6.68M 7.7%
- Americas - Other 3.23M 3.7%
Fiscal year ended Dec 31, 2025 See the full Harvard Bioscience breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 86.55M | -7.59M | -8.06% |
| Dec 31, 2024 | 94.14M | -18.12M | -16.14% |
| Dec 31, 2023 | 112.25M | -1.09M | -0.96% |
| Dec 31, 2022 | 113.34M | -5.57M | -4.68% |
| Dec 31, 2021 | 118.90M | 16.80M | 16.46% |
| Dec 31, 2020 | 102.10M | -14.08M | -12.12% |
| Dec 31, 2019 | 116.18M | -4.60M | -3.81% |
| Dec 31, 2018 | 120.77M | 43.37M | 56.02% |
| Dec 31, 2017 | 77.41M | -27.11M | -25.94% |
| Dec 31, 2016 | 104.52M | -4.14M | -3.81% |
| Dec 31, 2015 | 108.66M | 1.00K | - |
| Dec 31, 2014 | 108.66M | 3.49M | 3.32% |
| Dec 31, 2013 | 105.17M | -6.00M | -5.40% |
| Dec 31, 2012 | 111.17M | 2.31M | 2.12% |
| Dec 31, 2011 | 108.86M | 685.00K | 0.63% |
| Dec 31, 2010 | 108.18M | 22.41M | 26.12% |
| Dec 31, 2009 | 85.77M | -2.28M | -2.59% |
| Dec 31, 2008 | 88.05M | 4.64M | 5.57% |
| Dec 31, 2007 | 83.41M | 7.23M | 9.49% |
| Dec 31, 2006 | 76.18M | 8.75M | 12.98% |
| Dec 31, 2005 | 67.43M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KORU Medical Systems | 46.27M |
| Retractable Technologies | 37.95M |
| Precision Optics Corporation | 33.00M |
| Stereotaxis | 31.53M |
| Bionano Genomics | 31.09M |
| Nephros | 21.58M |
| Milestone Scientific | 9.28M |
| Anbio Biotechnology | 8.65M |
HBIO News
- 7 days ago - Harvard Bioscience downgraded to Hold from Speculative Buy at StoneX - TheFly
- 8 days ago - Harvard Bioscience reports Q3 adjusted EPS (6c), consensus (17c) - TheFly
- 8 days ago - Harvard Bioscience sees Q4 revenue $23.7M-$25.5M, consensus $24.5M - TheFly
- 8 days ago - Harvard Bioscience backs FY26 revenue view up 3%-5% - TheFly
- 8 days ago - Harvard Bioscience Earnings Call Transcript: Q3 2026 - Transcripts
- 8 days ago - Harvard Bioscience Earnings release: Q3 2026 - Filings
- 8 days ago - Harvard Bioscience Slides: Q3 2026 - Filings
- 8 days ago - Harvard Bioscience Quarterly report: Q3 2026 - Filings